Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW869682 in Obesity
NCT00297180Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing GW869682 with Placebo (2 arms). Primary endpoint: Percentage change in body weight at 12 weeks. Started Jan 2006; status: completed.
02
Drugs
Sergliflozin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00297180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297180.